HLI employs a combination of whole-genome sequencing, regular blood marker analysis, and advanced imaging techniques, which significantly enhance their success rate in preventing late-stage diagnoses.

Remarkably, in the past ten years, only one prostate cancer death has occurred among HLI members, underscoring the effectiveness of their early detection and intervention strategies.

In a bid to democratize healthcare services, HLI plans to reduce the cost of their comprehensive program from thousands to under a thousand dollars in the future.

HLI invites its members to join a collective effort to combat prostate cancer, highlighting the potential for significant advancements in personalized medicine.

Looking ahead, Dr. He believes that personalized longevity algorithms could revolutionize healthcare access, enabling individualized care for various cancers beyond just prostate cancer.

Additionally, HLI has pledged $1 million for advanced treatment for any member of its Executive Health Program who develops late-stage prostate cancer.

Founded in 2013 by Dr. J Craig Venter, Human Longevity, Inc. (HLI) is dedicated to extending human health through preventive approaches and analyzing health data to identify risks early.

HLI has developed an advanced algorithm for early prostate cancer detection, utilizing data from over 5,000 men collected over the last decade.

The company stresses the critical importance of early detection, noting that nearly 100% of prostate cancers diagnosed at stage one are curable, in stark contrast to a mere 30% five-year survival rate at stage four.

Dr. Wei-Wu He, HLI's chairman, acknowledges that current PSA tests are imperfect and emphasizes the goal of improving sensitivity and specificity for better prostate cancer detection.